Show simple item record

Hyperpigmentation due to pyrimethamine use

dc.contributor.authorEngin, A
dc.contributor.authorMert, A
dc.contributor.authorAktuglu, Y
dc.contributor.authorTabak, F
dc.contributor.authorOzturk, R
dc.contributor.authorOzaras, Reşat
dc.date.accessioned2021-03-05T09:21:07Z
dc.date.available2021-03-05T09:21:07Z
dc.date.issued2002
dc.identifier.citationOzturk R., Engin A., Ozaras R., Mert A., Tabak F., Aktuglu Y., "Hyperpigmentation due to pyrimethamine use", JOURNAL OF DERMATOLOGY, cilt.29, ss.443-445, 2002
dc.identifier.issn0385-2407
dc.identifier.otherav_9d74eec0-844a-49a2-88d5-3cb867d1e20e
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/105790
dc.identifier.urihttps://doi.org/10.1111/j.1346-8138.2002.tb00303.x
dc.description.abstractPyrimethamine is used for the treatment of tuxoplasmosis and the prophylaxis of malaria. Among the well-documented side effects are megaloblastic anemia, leukopenia, thrombopenia, rash, vomiting, and diarrhea. Hyperpigmentation is a very rare side effect. In some patients, associated HIV infection makes it difficult to distinguish the reasons for the etiology. We herein describe an HIV-negative patient who developed hyperpigmentation after pyrimethamine use.
dc.language.isoeng
dc.subjectDERMATOLOJİ
dc.subjectDahili Tıp Bilimleri
dc.subjectDermatoloji
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectSağlık Bilimleri
dc.titleHyperpigmentation due to pyrimethamine use
dc.typeMakale
dc.relation.journalJOURNAL OF DERMATOLOGY
dc.contributor.department, ,
dc.identifier.volume29
dc.identifier.issue7
dc.identifier.startpage443
dc.identifier.endpage445
dc.contributor.firstauthorID41087


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record